Table III.

Clinical and laboratory parameters before and after the use of IGlar U300

Parameter	Baseline (n = 35)	Final€ (n = 35)	P-value
Systolic blood pressure (SBP) [mm Hg]	120 [90–150]	120 [90–150]	0.676*
Diastolic blood pressure (DBP) [mm Hg]	70 [60–90]	70 [50–90]	0.394*
Total dose of basal insulin [U]	22 [10–50]	28 [6–54]	0.158*
IGlar U100 – IGlar U300 dose [U]	26.1 ±9.6	27.9 ±9.7	0.203**
I Detemir dose – IGlar U300 dose [U]	16 [10–50]	14 [8–54]	1.000*
IGlar U300 dose [U]	24 [8–50]	28 [6–54]	0.144*
Total dose of bolus insulin [U]	26 [6–76]	26 [5–64]	0.255*
Ratio of total dose of injected insulin to weight [unit/kg/day]	0.8 ±0.3	0.8 ±0.3	0.713**
Alanine aminotransferase (ALT) (N: 0–45 U/l)	12 [3–56]	10 [3–100]	0.910*
Low-density lipoprotein (N: < 160 mg/dl)	99 [44–190]	99.5 [42–190]	0.483*
Creatinine (N: 0.67–1.17 mg/dl)	0.6 [0.4–1.6]	0.6 [0.4–1.3]	0.680*
Glomerular filtration rate (GFR) [ml/min]	130 [54–148]	131 [69–152]	0.210*
Proteinuria (N: < 50 mg/dl)	0 [0–100]	0 [0–50]	0.907*
Hospitalization (n)	14	9
Ketosis	3	1

^*Wilcoxon signed-rank test,

^**Paired t-test.

^€Final measurement was defined as the patient’s last admission to the outpatient clinic between 9 and 16 months.